SCHEMBL2642567

SCHEMBL2642567

CC(=O)Nc1csc(CN)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
CDK5 Q00535 7/20 0.42
CDK5R1 Q15078 7/20 0.42
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCNA2 P20248 4/20 0.41
CDK2 P24941 4/20 0.41
CCNA1 P78396 4/20 0.41
AOC3 Q16853 3/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
MAPK8 P45983 1/20 0.40
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 2/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
LMNA P02545 1/20 0.37
MAOB P27338 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11508033 0.84 L3MBTL1 (0.44) L3MBTL1CDK5CDK5R1KMT2ASMN1; SMN2
SCHEMBL20558119 0.84 CDK5 (0.45) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL2644138 0.83 ADORA3 (0.45) CDK5CDK5R1KMT2ASMN1; SMN2CCNA2
SCHEMBL2642560 0.83 ADORA3 (0.43) L3MBTL1CDK5CDK5R1KMT2ASMN1; SMN2
SCHEMBL22031129 0.79 CDK5 (0.46) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL2642609 0.77 PIK3CG (0.53) L3MBTL1KMT2ASMN1; SMN2ADORA3ADORA2A
SCHEMBL2643481 0.77 LOXL2 (0.35) CDK5CDK5R1KMT2ASMN1; SMN2CCNA2
SCHEMBL11350463 0.74 L3MBTL1 (0.62) L3MBTL1KMT2ASMN1; SMN2AOC3KDM4E
SCHEMBL11358850 0.74 L3MBTL1 (0.48) L3MBTL1KMT2ASMN1; SMN2ADORA3ADORA2A
SCHEMBL2642653 0.74 GRM5 (0.44) L3MBTL1KMT2ASMN1; SMN2ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765789-B2 2-pyridinecarboxamide derivatives MSD K.K. (JP) 2014-07-01 US disclosed
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2013-04-04 US disclosed
US-8344003-B2 2-pyridinecarboxamide derivatives MSD K. K. (JP) 2013-01-01 US disclosed
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2010-02-18 US disclosed
US-7629362-B2 2-pyridine carboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 US disclosed
EP-1598349-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 L3MBTL1 4342/4885CDK5 717/4885CDK5R1 196/4885
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives GCKR, GCK, HK2 L3MBTL1 4359/4885CDK5 738/4885CDK5R1 189/4885
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 L3MBTL1 4342/4885CDK5 717/4885CDK5R1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.